Medtronic Yönetim

Yönetim kriter kontrolleri 2/4

Medtronic CEO'su Geoff Martha, Apr2020 tarihinde atandı, in görev süresi 4.58 yıldır. in toplam yıllık tazminatı $ 20.08M olup, şirket hissesi ve opsiyonları dahil olmak üzere 6.7% maaş ve 93.3% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.006% ine doğrudan sahiptir ve bu hisseler € 6.29M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.6 yıl ve 7.8 yıldır.

Anahtar bilgiler

Geoff Martha

İcra Kurulu Başkanı

US$20.1m

Toplam tazminat

CEO maaş yüzdesi	6.7%
CEO görev süresi	4.6yrs
CEO sahipliği	0.006%
Yönetim ortalama görev süresi	3.6yrs
Yönetim Kurulu ortalama görev süresi	7.8yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Geoff Martha'un ücretlendirmesi Medtronic'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Oct 25 2024	n/a	n/a	US$4b
Jul 26 2024	n/a	n/a	US$4b
Apr 26 2024	US$20m	US$1m	US$4b
Jan 26 2024	n/a	n/a	US$4b
Oct 27 2023	n/a	n/a	US$4b
Jul 28 2023	n/a	n/a	US$4b
Apr 28 2023	US$15m	US$1m	US$4b
Jan 27 2023	n/a	n/a	US$4b
Oct 28 2022	n/a	n/a	US$4b
Jul 29 2022	n/a	n/a	US$5b
Apr 29 2022	n/a	n/a	US$5b
Jan 28 2022	n/a	n/a	US$5b
Oct 29 2021	n/a	n/a	US$5b
Jul 30 2021	n/a	n/a	US$4b
Apr 30 2021	US$18m	US$1m	US$4b
Jan 29 2021	n/a	n/a	US$3b
Oct 30 2020	n/a	n/a	US$4b
Jul 31 2020	n/a	n/a	US$4b
Apr 24 2020	US$6m	US$905k	US$5b
Jan 24 2020	n/a	n/a	US$5b
Oct 25 2019	n/a	n/a	US$5b
Jul 26 2019	n/a	n/a	US$4b
Apr 26 2019	US$4m	US$693k	US$5b

Tazminat ve Piyasa: Geoff 'nin toplam tazminatı ($USD 20.08M ), German pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 4.74M ).

Tazminat ve Kazançlar: Geoff 'in maaşı son bir yılda %20'den fazla arttı.

CEO

Geoff Martha (54 yo)

4.6yrs

Görev süresi

US$20,084,630

Tazminat

Mr. Geoffrey Straub Martha, also known as Geoff, serves as Director at Medtronic plc since November 01, 2019 and serves as its Chief Executive Officer since April 27, 2020. He serves as Director of NextEra...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Geoffrey Martha	Chairman of the Board & CEO	4.6yrs	US$20.08m	0.0060% € 6.3m
Sean Salmon	Executive VP & President of Cardiovascular Portfolio	no data	US$6.55m	0.0021% € 2.2m
Brett Wall	Executive VP & President of Neuroscience Portfolio	5yrs	US$6.44m	0.00092% € 962.0k
Gregory Smith	Executive Vice President of Global Operations & Supply Chain	3.6yrs	US$7.66m	0.0015% € 1.5m
Gary Corona	Senior Vice President of Global Financial Planning and Analysis & Interim CFO	less than a year	Veri yok	0.00045% € 470.6k
Mark Ploof	Senior Vice President of Global Operations and Business Services	8.1yrs	Veri yok	Veri yok
Jennifer Kirk	Senior VP	3.4yrs	Veri yok	0.0022% € 2.3m
Kenneth Washington	Senior VP and Chief Technology & Innovation Officer	1.4yrs	Veri yok	Veri yok
Laura Mauri	Senior VP and Chief Scientific & Medical Officer	2.6yrs	Veri yok	Veri yok
Ryan Weispfenning	VP & Head of Investor Relations	9.4yrs	Veri yok	Veri yok
Ivan Fong	Executive VP	2.8yrs	US$11.72m	0.0019% € 2.0m
Torod Neptune	Senior VP & Chief Communications Officer	3.8yrs	Veri yok	Veri yok

3.6yrs

Ortalama Görev Süresi

59yo

Ortalama Yaş

Deneyimli Yönetim: 2M6 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.6 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Geoffrey Martha	Chairman of the Board & CEO	5yrs	US$20.08m	0.0060% € 6.3m
Scott Donnelly	Independent Director	11.8yrs	US$365.06k	0.0012% € 1.2m
Kendall Powell	Independent Director	17.8yrs	US$350.06k	0.0015% € 1.6m
Randall Hogan	Independent Director	9.8yrs	US$385.06k	0.0034% € 3.5m
Craig Arnold	Lead Independent Director	9.8yrs	US$410.06k	0.0028% € 2.9m
Andrea Goldsmith	Independent Director	5.7yrs	US$370.06k	0.00048% € 501.9k
Elizabeth Nabel	Independent Director	10.8yrs	US$370.06k	0.0010% € 1.1m
Lidia Fonseca	Independent Director	2.4yrs	US$350.06k	0.00012% € 125.5k
Kevin Lofton	Independent Director	4.2yrs	US$370.06k	0.00032% € 334.6k
Gregory Lewis	Independent Director	1.4yrs	US$306.97k	0% € 0

7.8yrs

Ortalama Görev Süresi

63yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 2M6 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 7.8 yıldır).

Medtronic Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Medtronic plc, Annual General Meeting, Oct 17, 2024

Medtronic plc Announces Resignation of Karen Parkhill as CFO

Medtronic plc Announces Retirement of Rob Ten Hoedt as Executive Vice President and President, Global Regions, Effective as of June 28, 2024

Medtronic plc Appoints Greg Lewis as New Director

Medtronic plc Appoints Ken Washington as Chief Technology and Innovation Officer

Recent updates

Second quarter 2025 earnings released: EPS: US$0.99 (vs US$0.68 in 2Q 2024)

Medtronic plc Receives FDA Clearance for New Inpen App, Pending the Way for Its Smart MDI System Launch with Simplera™? CGM

CMS Grants Transitional Pass-Through Payment for Medtronic Symplicity Spyral Renal Denervation Catheter

Medtronic plc Announces New, Long-Term Data from Its SPYRAL HTN-ON MED Clinical Trial

Medtronic plc Receives FDA Approval of Affera Mapping and Ablation System and Sphere-9 Catheter

Voluntary Recall Notifying Medtronic Insulin Pump Users of Potential Risks of Shortened Pump Battery Life

Medtronic plc Announces the Presentation of Clinical Study Results

Upcoming dividend of US$0.70 per share

First quarter 2025 earnings released: EPS: US$0.81 (vs US$0.59 in 1Q 2024)

Medtronic plc Revises Earnings Guidance for the Fiscal Year 2025

Fourth quarter dividend of US$0.70 announced

Medtronic plc Announces Cash Dividend for Second Quarter of Fiscal Year 2025, Payable on October 11, 2024

Medtronic plc, Annual General Meeting, Oct 17, 2024

Now 20% undervalued after recent price drop

New minor risk - Earnings quality

Medtronic plc Announces Resignation of Karen Parkhill as CFO

Full year 2024 earnings released: EPS: US$2.77 (vs US$2.83 in FY 2023)

Medtronic plc Announces Retirement of Rob Ten Hoedt as Executive Vice President and President, Global Regions, Effective as of June 28, 2024

Full year 2024 earnings released: EPS: US$2.77 (vs US$2.83 in FY 2023)

Medtronic plc Announces its Investigational OmniaSecure Defibrillation Lead Met its Primary Safety and Effectiveness Endpoints, Existing Safety and Effectiveness Endpoints

Medtronic plc Receives FDA Approval for Inceptiv Closed-Loop Spinal Cord Stimulator

Medtronic plc Announces New Advancements in Artificial Intelligence for Endoscopic Care by Unveiling ColonPRO

Medtronic plc Announces SMART Trial One-Year Data Demonstrates Medtronic Evolut™ Tavr Platform as Optimal Treatment for Severe Aortic Stenosis in Patients with Small Annulus, Which Is Primarily Women

Now 20% undervalued

Upcoming dividend of US$0.69 per share

Third quarter dividend of US$0.69 announced

Medtronic plc Presents New Clinical and Real-World Data on the MiniMed™ 780G System from Around the World

Medtronic plc Approves Cash Dividend for the Fourth Quarter of Fiscal Year 2024, Payable on April 12, 2024

Now 20% undervalued

Third quarter 2024 earnings released: EPS: US$0.99 (vs US$0.92 in 3Q 2023)

Now 20% undervalued

Medtronic plc to Report Q3, 2025 Results on Feb 18, 2025

Medtronic plc Announces FDA Approval of Its Percept™? RC Deep Brain Stimulation System

Medtronic Diabetes Announces World's First Approval for MiniMed™ 780G System with Simplera Sync™ Disposable, all-in-one sensor

Medtronic plc Announces FDA Approves the PulseSelect Pulsed Field Ablation System for the Treatment of Both Paroxysmal and Persistent Atrial Fibrillation

Upcoming dividend of US$0.69 per share at 3.5% yield

Medtronic Announces Cash Dividend for Third Quarter of Fiscal Year 2024, Payable on January 12, 2024

Second quarter 2024 earnings released: EPS: US$0.68 (vs US$0.32 in 2Q 2023)

Medtronic plc Revises Earnings Guidance for the Fiscal Year 2024

Medtronic plc Announces Four-Year Results from the Evolut Low Risk Trial

Now 20% undervalued after recent price drop

Orchestra BioMed Holdings, Inc Grants FDA Approval of IDE to Initiate BACKBEAT Pivotal Study of BackBeat CNT™ for the Treatment of Hypertension in Pacemaker Patients

Upcoming dividend of US$0.69 per share at 3.4% yield

Medtronic Issues Statement on the FDA Circulatory Systems Devices Advisory Panel vote for the Symplicity Spyral Renal Denervation System

Medtronic plc Raises Earnings Guidance for 2024

New minor risk - Profit margin trend

First quarter 2024 earnings released: EPS: US$0.59 (vs US$0.70 in 1Q 2023)

Medtronic plc Approves Cash Dividend for the Second Quarter of Fiscal Year 2024, Payable on October 13, 2023

Full year 2023 earnings released: EPS: US$2.83 (vs US$3.75 in FY 2022)

Medtronic plc Appoints Greg Lewis as New Director

Medtronic plc Presents New Data on MiniMed 780G System on Fixed Meal Dosing and Real-World Time in Range Across Wide Range of Users

Upcoming dividend of US$0.69 per share at 3.1% yield

Medtronic plc Appoints Ken Washington as Chief Technology and Innovation Officer

Full year 2023 earnings released: EPS: US$2.83 (vs US$3.75 in FY 2022)

Medtronic plc Approves Cash Dividend for the First Quarter of Fiscal Year 2024, Payable on July 14, 2023

Medtronic plc Announces Medtronic Extravascular ICD Global Clinical Trial Results Reinforce Device Safety and Effectiveness

Medtronic Extravascular ICD Global Clinical Trial Results Reinforce Device Safety and Effectiveness

Shockwave Medical Reportedly Picks Up Takeover Interest from Two Additional Suitors

Shockwave Medical Reportedly Picks Up Takeover Interest from Two Additional Suitors

Upcoming dividend of US$0.68 per share at 3.5% yield

Third quarter 2023 earnings released: EPS: US$0.92 (vs US$1.10 in 3Q 2022)

Medtronic plc to Report Q3, 2024 Results on Feb 20, 2024

Medtronic Linq Insertable Cardiac Monitor Detects 10 Times More Atrial Fibrillation in Ischemic Stroke Patients At Three Years Compared to Standard of Care

Siemens Healthineers, GE Healthcare Studying Potential Deals with Medtronic's Spun Off Units

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi